Zhu H - Search Results

1

TRAIL mutant membrane penetrating peptide alike (TMPPA) TRAIL‑Mu3 enhances the antitumor effects of TRAIL in vitro and in vivo.

Zhu H, Yan J, Xu Q, Wei L, Huang X, Chen S, Yi C. Zhu H, et al. Mol Med Rep. 2017 Dec;16(6):9607-9612. doi: 10.3892/mmr.2017.7791. Epub 2017 Oct 13. Mol Med Rep. 2017. PMID: 29039511

2

Generation of a novel TRAIL mutant by proline to arginine substitution based on codon bias and its antitumor effects.

Zhu A, Wang X, Huang M, Chen C, Yan J, Xu Q, Wei L, Huang X, Zhu H, Yi C. Zhu A, et al. Among authors: zhu h. Mol Med Rep. 2017 Oct;16(4):4973-4979. doi: 10.3892/mmr.2017.7146. Epub 2017 Aug 2. Mol Med Rep. 2017. PMID: 28791342

3

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer.

Huang M, Zhu H, Yi C, Yan J, Wei L, Yang X, Chen S, Huang Y. Huang M, et al. Among authors: zhu h. Cancer Chemother Pharmacol. 2018 Nov;82(5):829-838. doi: 10.1007/s00280-018-3658-9. Epub 2018 Aug 24. Cancer Chemother Pharmacol. 2018. PMID: 30167846

4

Gemcitabine plus S-1 for metastatic pancreatic cancer.

Zhu H, Yi C, Zhao Y, Gou H. Zhu H, et al. Medicine (Baltimore). 2018 Oct;97(41):e12836. doi: 10.1097/MD.0000000000012836. Medicine (Baltimore). 2018. PMID: 30313120 Free PMC article.

5

Treatment with Brivanib alaninate as a second-line monotherapy after Sorafenib failure in hepatocellular carcinoma: A case report.

Zhu H, Zhang C, Yang X, Yi C. Zhu H, et al. Medicine (Baltimore). 2019 Mar;98(10):e14823. doi: 10.1097/MD.0000000000014823. Medicine (Baltimore). 2019. PMID: 30855507 Free PMC article.

6

Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo.

Ding W, Cai T, Zhu H, Wu R, Tu C, Yang L, Lu W, He Q, Yang B. Ding W, et al. Among authors: zhu h. Cancer Lett. 2010 Jul 28;293(2):158-66. doi: 10.1016/j.canlet.2010.01.005. Epub 2010 Feb 6. Cancer Lett. 2010. PMID: 20137855

7

Resistance of SMMC-7721 hepatoma cells to etoposide in hypoxia is reversed by VEGF inhibitor.

Shi S, Yuan C, Zhuang K, Liang G, Yao Z, Wang D, Weng Q, Cao J, Luo P, Zhu H, Ding L, Ma S. Shi S, et al. Among authors: zhu h. Mol Med Rep. 2015 May;11(5):3842-7. doi: 10.3892/mmr.2015.3217. Epub 2015 Jan 16. Mol Med Rep. 2015. PMID: 25607114

8

Up-regulation of death receptor 4 and 5 by celastrol enhances the anti-cancer activity of TRAIL/Apo-2L.

Zhu H, Liu XW, Ding WJ, Xu DQ, Zhao YC, Lu W, He QJ, Yang B. Zhu H, et al. Cancer Lett. 2010 Nov 28;297(2):155-64. doi: 10.1016/j.canlet.2010.04.030. Epub 2010 Jun 1. Cancer Lett. 2010. PMID: 20605676

9

RITA enhances irradiation-induced apoptosis in p53-defective cervical cancer cells via upregulation of IRE1α/XBP1 signaling.

Zhu H, Abulimiti M, Liu H, Su XJ, Liu CH, Pei HP. Zhu H, et al. Oncol Rep. 2015 Sep;34(3):1279-88. doi: 10.3892/or.2015.4083. Epub 2015 Jun 25. Oncol Rep. 2015. PMID: 26134873

10

Deubiquitinating enzyme USP10 promotes hepatocellular carcinoma metastasis through deubiquitinating and stabilizing Smad4 protein.

Yuan T, Chen Z, Yan F, Qian M, Luo H, Ye S, Cao J, Ying M, Dai X, Gai R, Yang B, He Q, Zhu H. Yuan T, et al. Among authors: zhu h. Mol Oncol. 2020 Jan;14(1):197-210. doi: 10.1002/1878-0261.12596. Epub 2019 Nov 27. Mol Oncol. 2020. PMID: 31721429 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

30,468 results

Search Page

Filters